81 results about "Structural analog" patented technology

The invention relates to a hybridoma cell strain capable of secreting a mefos monoclonal antibody and application of the hybridoma cell strain, and belongs to the technical field of immunodetection. According to the invention, the hybridoma cell strain capable of secreting the fenofos monoclonal antibody is obtained through screening, the fenofos monoclonal antibody has high specificity and high sensitivity to the fenofos, IC50 to the fenofos is 0.231 ng / mL, and the fenofos monoclonal antibody has no cross reaction to structural analogues of the fenofos, such as triazophos, diazinon, phorate, acetyl phorate, methamidophos and the like; therefore, low-concentration isoprophos can be accurately detected.

The invention relates to a hybridoma cell strain capable of secreting dextromethorphan monoclonal antibody and application of the hybridoma cell strain, and belongs to the technical field of immunodetection. The monoclonal antibody secreted by the hybridoma cell strain disclosed by the invention has good sensitivity and specificity on dextromethorphan, wherein the IC50 value on the dextromethorphan is 0.162 ng / mL. The monoclonal antibody provided by the invention has no cross reaction on structural analogues of dextromethorphan, such as fentanyl, thilazine, papaverine, morphine and medetomidine, and has good specificity, so that the dextromethorphan with low concentration can be accurately detected.

The invention relates to a method for specifically detecting tetrahydrocannabinol and hydride thereof by utilizing bridged beta-cyclodextrin, and belongs to the technical field of analysis and detection of supramolecular materials. The method comprises the following steps: firstly, combining 1, 6-hexamethylenediamine bridged bis-beta-cyclodextrin with an indicator to form a supramolecular probe; in a buffer system with a pH value of 9-11, tetrahydrocannabinol or a hydride thereof specifically competes to be combined with a cavity and displaces an indicator by utilizing a synergistic inclusion effect of a bridging subject and dissociation difference of guest molecules, so that the system is subjected to fluorescence quenching or color change, and a structural analogue cannabidiol does not generate obvious interference. The method solves the problems that the sensitivity is low and cannabidiol cannot be effectively distinguished in the prior art through cooperation of specific main body construction and environment regulation, has the advantages of being rapid in detection, high in specificity, high in accuracy and the like, and is suitable for environment monitoring and field screening.

The present invention provides diazo compounds having anti-trypanosomal activity, with less or no side-effects. The diazo compounds are structural analogue of quinapyramine and possess characteristics necessary for the targeted pharmacologic action of anti trypanosomosis, with reduced cytotoxicity. The compounds were found to have less cytotoxicity, and identical or better anti- parasitemia effect as compared to conventional quinapyramine sulfate.

This invention belongs to the field of immunology and discloses a hybridoma cell line and the preparation and application of its secreted monoclonal antibody that uniformly recognizes tylosin / tilmicosin. The monoclonal antibody hybridoma cell line is named DES-AOAA-14D5, with accession number CGMCC NO: 45303. This invention utilizes decarboxymethyl tylosin and oxycarboxymethyl hydroxylamine to synthesize a hapten, conjugates a carrier protein to prepare a complete antigen, immunizes mice, and, through cell fusion and screening techniques, prepares a hybridoma cell line that can secrete a monoclonal antibody that uniformly recognizes tylosin / tilmicosin. IC50 50 The effective concentrations were 1.59 and 1.72 ng / mL, respectively, with a cross-reactivity rate as high as 92.44%. An immunoassay method for the simultaneous and accurate detection of tylosin / tilmicosin in milk was established using this antibody. The cut-off value for both tylosin and tilmicosin was 16 ng / mL, and no cross-reactivity was observed with other structural analogs. The detection method of this invention shows promising application prospects.

The application belongs to the technical field of chemical analysis and detection, and discloses a zinc oxide quantum dot fluorescent sensor and application of the zinc oxide quantum dot fluorescent sensor in detection of kaempferol. The zinc oxide quantum dot fluorescent sensor is prepared by stirring zinc salt solution and lye uniformly, then adding amino silane and water to carry out sol-gel reaction to prepare a ZnO-QDs fluorescent probe solution; then, a substrate is immersed in the ZnO-QDs fluorescent probe solution to carry out incubation, and drying is carried out to obtain the zinc oxide quantum dot fluorescent sensor. S The zinc oxide quantum dot fluorescent sensor is applied to detection of kaempferol, can produce specific response with kaempferol, makes the fluorescence intensity of the ZnO-QD fluorescent probe gradually increase with the increase of the concentration of kaempferol, and can effectively exclude the interference of structural analogs such as quercetin and luteolin, so that the kaempferol in the sample can be accurately quantified; and the detection cost is low, the operation is convenient, the detection efficiency is high, the detection is green and safe, and the zinc oxide quantum dot fluorescent sensor is suitable for popularization and application.

The application discloses a nucleic acid aptamer OUC-Fx11-5T of fucoxanthin and application thereof, and belongs to the technical field of nucleic acid aptamer. The nucleic acid aptamer OUC-Fx11-5T of fucoxanthin has a nucleotide sequence as shown in SEQ ID NO. 19. The nucleic acid aptamer OUC-Fx11-5T of fucoxanthin is applied to the recognition or detection of fucoxanthin. The nucleic acid aptamer OUC-Fx11-5T of fucoxanthin has an affinity dissociation constant of 68.2 nM with fucoxanthin by isothermal titration calorimetry, has no obvious affinity to structural analogs of fucoxanthin such as violaxanthin, neoxanthin, zeaxanthin and beta-carotene, has high affinity and good specificity to fucoxanthin, and can be used for the recognition or detection of fucoxanthin.

The invention relates to a hybridoma cell strain secreting a mepiquat chloride monoclonal antibody and application of the hybridoma cell strain, and belongs to the technical field of immunodetection. The hybridoma cell strain is preserved in China General Microbiological Culture Collection Center (CGMCC) on April 17, 2025, the preservation address is No.3, No.1 Yard, Beichen West Road, Chaoyang District, Beijing, and the preservation number is CGMCC No.46517. The monoclonal antibody secreted by the hybridoma cell strain has good sensitivity and specificity to mepiquat chloride, the IC50 value of the mepiquat chloride is 4.981 ng / mL, structural analogues and functional analogues of the mepiquat chloride, such as chlormequat chloride, paclobutrazol and uniconazole, have no cross reaction, the cross reaction rate is smaller than 1%, and the monoclonal antibody secreted by the hybridoma cell strain can be used for preparing the mepiquat chloride monoclonal antibody. Therefore, low-concentration mepiquat chloride can be accurately detected.

The application discloses an anti-cyprodinil monoclonal antibody and application thereof. The light chain variable region of the anti-cyprodinil monoclonal antibody has an amino acid sequence shown in SEQ ID No. 1, and the heavy chain variable region has an amino acid sequence shown in SEQ ID No. 2. The monoclonal antibody has good affinity to cyprodinil, the half-inhibitory concentration (IC 50 ) is 4.55 ng / mL, the detection limit (IC 10 ) is 1.34 ng / mL, the linear range (IC 20 ~ IC 80 ) is 2.11~9.83 ng / mL, the cross-reaction rate of structural analogs such as fenamidone, bifenox and pheonox is less than 1%, the monoclonal antibody has the characteristics of good thermal stability, strong resistance to organic solvents and acid and alkali, high sensitivity, and is suitable for detecting cyprodinil residues in different environments.

The invention belongs to the technical field of organic synthesis, and particularly relates to a preparation method and application of a 2-phenyl-2H-chromene compound. According to the method, benzaldehyde and o-hydroxyacetophenone are taken as initial raw materials, Claisen-Schmidt condensation is carried out under an alkaline condition to prepare 2-hydroxychalcone, NaBH4 is utilized to reduce carbonyl to prepare an intermediate 2-(1-hydroxy-3-phenyl allyl) phenol, and then in an alkaline environment created by organic alkali Et3N, a 2-phenyl-2H-chromene skeleton is constructed by utilizing the complexing effect of BTC for the first time. According to the synthesis route, the synthesis efficiency of the chromene is remarkably improved, a practical method is provided for rapidly constructing a 2-phenyl-2H-chromene skeleton, and an important foundation is laid for efficient synthesis and structure-function relationship research of the chromene and structural analogues thereof.

The invention provides a conformation-locked amphibian skin peptide derivative or a pharmaceutically acceptable salt thereof. The conformation-locked amphibian skin peptide derivative or the pharmaceutically acceptable salt thereof has a structural formula shown in the specification or a structural analogue thereof, x is derived from one amino acid in TLa, the sequence of the TLa is LLRHVVKILEKYL, and (X) 3 is composed of any continuous sequences in three TLa. The invention also provides a preparation method of the tumor microenvironment response type TLa derivative-STING agonist MSA-2 conjugate and an application of the tumor microenvironment response type TLa derivative-STING agonist MSA-2 conjugate in tumor immunotherapy. In-vivo experiments show that the conjugate can effectively inhibit primary tumor growth and distal pulmonary metastasis in a melanoma model, and tumors of part of mice can completely fade away. The conjugate disclosed by the invention is expected to be developed into a novel efficient and low-toxicity tumor immunotherapy drug.

The invention belongs to the technical field of beta-carotene treatment, and discloses a purification method of beta-carotene fermentation broth, which comprises the following steps: S1, pretreatment: adding a composite antioxidant with the mass percentage of 0.01%-0.1% into the fermentation broth, and then removing thalli and large-particle impurities through centrifugation or microfiltration; and S2, carrying out supercritical CO2 extraction. By integrating supercritical CO2 extraction, molecular imprinting adsorption, multi-stage membrane separation, programmed cooling crystallization and other technologies, the method has the following remarkable advantages that on one hand, efficient separation and purification are achieved, the selective separation efficiency of beta-carotene is remarkably improved through the synergistic effect of the supercritical CO2 extraction and molecular imprinting technologies, and the separation efficiency of beta-carotene is greatly improved; the impurities of structural analogues such as carotenoid in the fermentation liquor are effectively removed; on the other hand, the impurities with different molecular weights are accurately removed through the graded purification effect of the multi-stage membrane separation system, and the product purity is greatly improved.

The invention discloses a method for synchronously detecting quaternary ammonium salts with different polarities and structural analogues thereof in high-organic-matter soil / sediment. The method comprises the following steps: performing freeze drying and low-temperature homogeneous grinding on a soil or sediment matrix sample, adding an internal standard substance and an extracting agent, performing vortex mixing, performing ultrasonic extraction, and performing low-temperature and high-speed centrifugation to obtain an extracting solution; heating in a water bath, carrying out nitrogen blowing concentration on an extracting solution until the extracting solution is nearly dry to obtain a concentrated solution, carrying out purification, leaching and impurity removal on the concentrated solution in a methanol-activated solid-phase extraction column, concentrating an eluent, adding a recovery rate indicator, and fixing the volume to obtain a sample to be detected; and detecting the sample to be detected by adopting an ultra-high performance liquid chromatography-tandem triple quadrupole mass spectrometer. According to the method, quaternary ammonium salts with different polarities and structural analogues thereof can be accurately quantified, and compared with a traditional method, the pollutant detection class group is wider, the recovery rate of substances to be detected is high, and the stability is higher.

The application discloses a hapten of abamectin B1a and / or its structural analog, an artificial antigen and application thereof. The application connects a spacer to abamectin after hydrolysis to obtain a hapten of abamectin B1a and / or its structural analog, and then connects a carrier protein to prepare an artificial antigen, and further prepare a monoclonal antibody. A chemiluminescence immunoassay method is established according to specific recognition of the antibody and the antigen, and abamectin residues in a sample are detected. The method can be used for trace detection of abamectin residues, and can avoid a complicated pretreatment step. The detection limit is 0.03 ng / mL, the IC 50 (50% inhibitory concentration) is 0.1 ng / mL, and the linear range IC 20 ~IC 80 is 0.04-0.20 ng / mL.

The invention discloses a chloramphenicol hapten, antigen, antibody and colloidal gold detection device as well as a preparation method and application thereof. According to the chloramphenicol hapten prepared by using a total synthesis method, all potential recognition sites of chloramphenicol are reserved to the maximum extent, particularly, the most critical dichloro structure of chloramphenicol is reserved for the first time, after a spacer arm is introduced, the distribution of electron cloud of the hapten is almost consistent with that of overall electron cloud of chloramphenicol, and the immunogenicity of the chloramphenicol antigen is improved; the chloramphenicol antigen and the monoclonal antibody prepared by the invention are high in specificity when being used for ELISA detection, the IC50 value is 8.21 pg / mL, the linear detection range is 1.71-39.45 pg / mL, and the cross reaction rates of the chloramphenicol antigen and the monoclonal antibody to common structural analogues are lower than 0.01%; and the sensitivity to chloramphenicol in a sample is 0.1 g / kg.

The invention relates to fluorescent metal organic gel Zr-TCBPE-MOG as well as a preparation method and application of the fluorescent metal organic gel Zr-TCBPE-MOG. The preparation method of the organic gel Zr-TCBPE-MOG comprises the following steps: dissolving zirconium chloride, 1, 1, 2, 2-tetra (4-carboxybenzene) ethylene and acetic acid in N, N-dimethylformamide, and then heating and cooling the mixture to obtain light yellow gel, namely the Zr-TCBPE-MOG. According to the invention, the synthesized fluorescent metal organic gel Zr-TCBPE-MOG is used as a fluorescent probe, piceatannol is successfully and specifically recognized from five structural analogues of piceatannol, pterostilbene, pinocembrin, Danjie rheum emodin and resveratrol, and according to the remarkable fluorescence quenching effect of piceatannol on the MOG material, the fluorescence intensity of the MOG material can be effectively improved. The piceatannol fluorescence detection method which is simple, convenient, rapid, ultra-sensitive and high in selectivity is successfully established.

The application provides a hybridoma cell strain secreting monoclone antibody of diquat and application thereof, and relates to the technical field of immune detection. The monoclone antibody secreted by the hybridoma cell strain has good sensitivity to diquat, the IC 50 1.13 ng / mL, so that the monoclone antibody can detect trace diquat. In addition, the monoclone antibody has no cross reaction to structural analogs of diquat, such as alachlor, acetochlor, butachlor, propanil, diquat and diquat, so that the monoclone antibody can accurately detect low concentration diquat.

The application discloses a DNA polymerase III mutant and application thereof. The mutant contains an amino acid sequence shown in SEQ ID No. 1, and the mutant can be applied to improving the mutation frequency of a host strain genome. In the application, the Escherichia coli is used as a starting strain, a high-efficiency evolution auxiliary plasmid is introduced, and the mutation frequency of the host is improved; combined with competitive pressure directional screening of a tryptophan structural analog 5MT, finally, the Escherichia coli engineering strain with high yield of tryptophan is obtained. The auxiliary plasmid comprises a pBad24 plasmid vector skeleton and an engineered Escherichia coli DNA polymerase III danQ nucleotide fragment. The high-efficiency evolution auxiliary plasmid provided by the application can significantly improve the mutation rate of the host genome, combined with the directional screening of 5MT, the traditional mutagenesis cycle can be greatly shortened, the engineering strain with high yield of tryptophan can be efficiently screened, and the application has important application value.

Methods and compositions are disclosed for rapidly relieving symptoms in subjects with depressive, stressor and substance abuse conditions, e.g., major depression, treatment-resistant depression, post-partum depression, bipolar depression, post-traumatic stress disorder, substance use disorders, negative and cognitive symptoms of schizophrenia, as well as for slowing progression of mild cognitive impairment and dementia, using an intermittent dosing regimen of memantine or amantadine or a structural analogue or pharmaceutically acceptable salt of memantine or amantadine (optionally no more frequently than every 2 days) at a dose sufficient to activate Set A brain structures, in combination with a second drug at a dose which activates Set B brain structures but which does not appreciably evoke brain activity linked to hallucinogenic and other psychotomimetic perceptions. In some instances the second drug is either 1) a low dose psilocybin or low dose of other psychedelic and stimulant molecules capable of activating Set B of brain structures which is administered at a dose low enough such that it does not appreciably evoke brain activity linked to hallucinogenic and other psychotomimetic perceptions, or is 2) mianserin (S isomer, R isomer, or a racemate comprising both isomers or structural analog or pharmaceutically acceptable salt thereof) or another standard of care antidepressant capable of activating Set B brain structures, or 3) lumateperone or another antipsychotic capable of activating Set B brain structures.

The invention relates to a hybridoma cell strain capable of secreting a diallyl phthalate monoclonal antibody and application of the hybridoma cell strain, and belongs to the technical field of immunodetection. The monoclonal antibody secreted by the hybridoma cell strain has excellent affinity and sensitivity to diallyl phthalate, IC50 of the monoclonal antibody to the diallyl phthalate reaches 500 ng / mL, and the monoclonal antibody secreted by the hybridoma cell strain has excellent affinity and sensitivity to structural analogues of the diallyl phthalate. The invention relates to a method for preparing diisononyl phthalate, which is characterized in that the diisononyl phthalate, such as dimethyl phthalate, diethyl phthalate, dinonyl phthalate, butyl benzyl phthalate, diisobutyl phthalate, di (2-ethylhexyl) phthalate and diisononyl phthalate, are not subjected to cross reaction. Therefore, the monoclonal antibody provided by the invention can be used for preparing an immunodetection product of diallyl phthalate, and an efficient detection method and means are provided for residue detection of diallyl phthalate in food.

The present application relates to a kind of secreting voriconazole monoclonal antibody hybridoma cell strain and its application, belong to immune detection technical field.The present application is prepared by screening and obtains a kind of hybridoma cell strain capable of secreting voriconazole monoclonal antibody, the monoclonal antibody secreted by the hybridoma cell strain of the present application has good sensitivity and specificity to voriconazole, specifically, the IC 50 Value of the monoclonal antibody of the present application to voriconazole is 10 ng / mL, and the cross-reactivity of voriconazole structural analog (fluconazole, posaconazole, albaconazole) is less than 10%, so that low concentration of voriconazole can be accurately detected.

The invention relates to a hybridoma cell strain capable of secreting a creatinine monoclonal antibody and application of the hybridoma cell strain, and belongs to the technical field of immunodetection. The monoclonal antibody secreted by the hybridoma cell strain has good sensitivity and specificity to creatinine, and the IC50 value of the monoclonal antibody to the creatinine is 0.277 g / mL and is far lower than the minimum IC50 value in the prior art. The monoclonal antibody provided by the invention has no cross reaction on structural analogues of creatinine, such as histidine, aminophylline, uric acid, uracil, guanine, adenine, cytosine, L-tryptophan, urea and 2-imino-1-imidazolidine acetic acid, and has good specificity, so that the low-concentration creatinine can be accurately detected.

The invention relates to a preparation method of a beta-endarphin (beta-endarphin, human) detection kit using a chemiluminescence immunoassay technology, and particularly relates to a preparation method of a beta-endarphin (beta-endarphin, human) detection kit. Endophalin is also called as brain endophine, is a morphine-like biochemical synthetic hormone and is secreted by pituitary gland. Beta-enorphin is small in molecular weight and poor in immunogenicity and has various structural analogues, so that when a corresponding antibody is prepared, firstly, a proper derivative site needs to be selected, and a derived hapten is coupled with a specific macromolecular carrier to prepare a complete antigen. The invention mainly relates to the design and synthesis of a beta-enorphin hapten, the preparation of a beta-enorphin complete antigen and an anti-beta-enorphin antibody, a method for measuring the concentration of beta-enorphin, and composition and components of a reagent. The design and synthesis of the hapten mainly comprise design and chemical synthesis of a beta-ennorphin derivative. The beta-ennorphin derivative disclosed by the invention has a structure as shown in a formula (I) which is described in the specification.

The group of inventions relates to the field of molecular biology, virology and medicine, and more particularly to novel reagents for the cotranscriptional capping of synthetic mRNA and to a method for producing same. The proposed reagent can be used to produce functional mRNA containing a 5' cap structure analog. The group of inventions makes it possible to create an mRNA cap structure analog that is cotranscriptionally incorporated into the structure of the mRNA and provides for more efficient mRNA translation.

The invention relates to a hybridoma cell strain secreting an isavuconazole monoclonal antibody and application of the hybridoma cell strain, and belongs to the technical field of immunodetection. The monoclonal antibody secreted by the hybridoma cell strain has good sensitivity and specificity to the isavuconazole, the IC50 value of the monoclonal antibody to the isavuconazole is 13.317 ng / mL, and the IC50 value of the monoclonal antibody to the structural analogue of the isavuconazole is 13.317 ng / mL. According to the present invention, the low-concentration isavuconazole, such as fluconazole, ketoconazole, posaconazole, clotrimazole, miconazole, econazole, voriconazole, bifenconazole, luliconazole and sertaconazole, does not have the cross reaction, and the cross reaction rate is less than 1%, such that the low-concentration isavuconazole can be accurately detected.

The invention relates to a hybridoma cell strain secreting a thifluzamide monoclonal antibody and application of the hybridoma cell strain, and belongs to the technical field of immunodetection. The monoclonal antibody secreted by the hybridoma cell strain has good sensitivity and specificity to thifluzamide, and the IC50 value of the monoclonal antibody to thifluzamide is 0.42 ng / mL and is far lower than the minimum IC50 value of an existing monoclonal antibody. The monoclonal antibody provided by the invention has no cross reaction on structural analogues of thifluzamide, such as furoxime amide, flutolanil, fluazifop-p-butyl, hexaflumuron, acifluorfen and pyrimethanil, and has good specificity, so that the thifluzamide with low concentration can be accurately detected.

This invention discloses a pyraclostrobin hapten, an artificial antigen, and their applications. The hapten prepared by this invention avoids the common backbone of structural analogs, fully exposes the unique characteristic structure of pyraclostrobin, and prepares highly specific and sensitive pyraclostrobin antibodies. Simultaneously, it simplifies the synthesis steps of the pyraclostrobin hapten, provides two novel pyraclostrobin haptens, and establishes an indirect competitive ELISA detection method for pyraclostrobin. The limit of detection (LOD) is 0.23 ng / mL, the quantitative detection range is 0.57–12.57 ng / mL, and there is no cross-reactivity with pyraclostrobin analogs. This method can be widely used for large-scale, rapid, and accurate screening of pyraclostrobin.

The present application belongs to a novel chromatographic stationary phase, and particularly relates to a preparation method of a cyclodextrin chromatographic stationary phase. The present application adopts tetrafluoro-p-phenylenedinitrile as a representative spacer, is easy to be crosslinked with cyclodextrin to generate a crosslinked cyclodextrin compound with a high specific surface area, and solves the problem of low cyclodextrin bonding amount of the traditional cyclodextrin chromatographic stationary phase. The chromatographic stationary phase can provide pi-pi interaction, hydrogen bond interaction and steric hindrance effect for the separation and analysis of structural analogs, and the inclusion effect of the cyclodextrin hydrophobic cavity is mutually coordinated and cooperated, the selectivity for the structural analogs is improved, and a unique separation effect is generated. As shown in the experimental example 1 of the present application, the peak orders of the compounds with similar structures on the present chromatographic column and the C18 column are different, and the separation selectivity is different. For the compounds which are difficult to separate, a new selectable chromatographic stationary phase is provided, and the separation efficiency of the C18 chromatographic stationary phase is improved.

This invention relates to a hybridoma cell line that secretes linezolid monoclonal antibodies and its applications, belonging to the field of immunoassay technology. Through multiple screening processes, this invention has obtained a hybridoma cell line that secretes linezolid monoclonal antibodies. The linezolid monoclonal antibody secreted by this hybridoma cell line exhibits excellent affinity and sensitivity to linezolid, with a high IC50 value for linezolid. 50 The concentration reaches 50 ng / mL, and there is no cross-reactivity with linezolid structural analogs, such as terdizolid and contezolid. Therefore, the monoclonal antibody of this invention can be used to prepare immunoassay products for linezolid, providing an efficient detection method and means for the detection of linezolid residues in food.

The application discloses a fengycin mimotope peptide which can be specifically combined with fengycin antibody, and a sensitive and rapid competitive enzyme-linked immunoassay method can be established by using the phage displaying the mimotope peptide or the mimotope peptide. 50 The IC50 is 0.30 ng / mL, and the LOD is 0.02 ng / mL, and the sensitivity of the method is improved by 60 times compared with the sensitivity of a traditional enzyme-linked immunoassay method based on a hapten; the competitive immunoassay method based on the mimotope peptide has good cross reactivity to other common structural analogues.